ARVINAS INC. news, videos and press releases - Page 3
For more news please use our advanced search feature.
ARVINAS INC. - More news...
ARVINAS INC. - More news...
- Arvinas Announces Changes to its Board of Directors
- Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)
- Arvinas Reports Third Quarter 2022 Financial Results and Provides Corporate Update
- Arvinas to Present at Upcoming Conferences
- Arvinas Announces Winner of the 2022 Arvinas Early Career Researcher Award
- Arvinas Appoints Paul McInulty as Senior Vice President, Regulatory Affairs
- Arvinas Gives Back to Local Greater New Haven Community
- Arvinas to Present at Bank of America Securities Precision Oncology Conference
- Arvinas to Present at Upcoming Investor Conferences
- Arvinas Announces Changes to its Board of Directors
- Arvinas Appoints Lisa Sinclair as Senior Vice President, Corporate Operations
- Arvinas Reports Second Quarter 2022 Financial Results and Provides Corporate Update
- Arvinas Appoints John Northcott as Chief Commercial Officer
- Arvinas to Present at Goldman Sachs 43rd Annual Global Healthcare Conference
- Arvinas Launches Global Early Career Researcher Award and Announces Call for Nominations
- Arvinas Reports First Quarter 2022 Financial Results and Provides Corporate Update
- Arvinas to Present at Upcoming Investor Conferences
- Arvinas Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
- Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer
- Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to be Presented at 2022 ASCO GU Meeting
- Arvinas to Present at Upcoming Investor Conferences
- Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
- Arvinas and Pfizer Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium
- Arvinas to Present at Stifel 2021 Virtual Healthcare Conference
- Arvinas Reports Third Quarter 2021 Financial Results and Provides Corporate Update
- Arvinas to Participate in Upcoming Virtual Investor Conferences
- Arvinas Reports Second Quarter 2021 Financial Results and Provides Corporate Update
- Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471
- Arvinas Participates in Groundbreaking Ceremony for New Space Within Downtown Crossing Development in New Haven
- Arvinas to Present at the 42nd Annual Goldman Sachs Global Healthcare Conference
